Your guide to therapy with Vsiqq® (brolucizumab)

For the treatment of neovascular (wet) age-related macular degeneration (AMD).

Date of preparation: June 2022
Version number 481191/VSI/A4/06.2022/240 v8.1
Published: September 2022
Quantities: 240
"Help to the health care professionals. Issued as a part of the Risk Management Plan.
This is not promotional material.
Before prescribing this medicine, please read the instructions for medical use.

NOVARTIS

 <insert date of approval by local competent authority> v8.1

What is neovascular (wet) age-related macular degeneration (AMD)?

Wet AMD occurs when abnormal blood vessels form and grow underneath the macula. The macula, which is at the back of the eye, is responsible for clear vision. The abnormal blood vessels may leak fluid or blood into the eye and interfere with the macula's function, resulting in decreased vision.

Date of preparation: June 2022
Version number 481191/VSI/A4/06.2022/240 v8.1
Published: September 2022
Quantities: 240
"Help to the health care professionals. Issued as a part of the Risk Management Plan.
This is not promotional material.
Before prescribing this medicine, please read the instructions for medical use.

Why have I been prescribed Vsiqq®?

Vsiqq® contains the active substance brolucizumab, which belongs to a group of medicines called anti-neovascularization agents.

A substance called vascular endothelial growth factor A (VEGF-A) causes the growth of blood vessels in the eye. By attaching to VEGF-A, Vsiqq® blocks its effect and reduces the growth of abnormal blood vessels in wet AMD which in turn reduces the leakage of fluid or blood in the eye.

How is Vsiqq® administered?

- Vsiqq® is injected into eye (intravitreal injection) by your doctor
- Your doctor will do some eye tests after injection. These tests may include measuring the pressure inside eye or assessing the condition of optic nerve.

© 2022 Novartis 3/22 184552 <insert date of approval by local competent authority> v8.1

What to expect after treatment

Sometimes, after an intravitreal injection such as Vsiqq®, the following may occur:

- An uncommon severe inflammation (endophthalmitis), usually associated with infection, inside the eye or a detachment of one of the layers in the back of the eye (retinal detachment/tear)
- A temporary increase in eye pressure (intraocular pressure), which is common but usually without symptoms; the doctor needs to do measurements of the pressure inside the eye to detect this

Important risk information

- Inflammation of the blood vessels in the retina (retinal vasculitis) and/or blockage of the blood vessels in the eye (retinal vascular occlusion), or a less severe inflammation in the eye (intraocular inflammation) may occur. You may be more at risk if you are female or of Japanese ethnicity
  - If you have had intraocular inflammation and/or retinal vascular occlusion in the last year, you are at increased risk of developing retinal vasculitis and/or retinal vascular occlusion
- An immune response (immunogenicity) is possible

Date of preparation: June 2022
Version number 481191/VSI/A4/06.2022/240 v8.1
Published: September 2022
Quantities: 240
"Help to the health care professionals. Issued as a part of the Risk Management Plan.
This is not promotional material.
Before prescribing this medicine, please read the instructions for medical use.

What to expect after treatment (cont)

Seek immediate medical help if you experienceany of the following:

A sudden decrease or changein your vision

New or increased number of floaters (small particles in vision)

Overall redness of the eye

New or persistent eye pain

orworsening eye discomfort

Flashes of light or increased sensitivity to light (discomfort from bright lights)

t can I do after my treatment?

After injection, your vision may be orarily affected (for example, blurred n). Do not drive or use machines as as these side effects last

oactive and tell your doctor or nurse notice any changes to your vision

It is important to follow the visit schedule mmended by your doctor

© 2022 Novartis 3/22 184552 <insert date of approval by local competent authority> v8.1

Date of preparation: June 2022
Version number 481191/VSI/A4/06.2022/240 v8.1
Published: September 2022
Quantities: 240
"Help to the health care professionals. Issued as a part of the Risk Management Plan.
This is not promotional material.
Before prescribing this medicine, please read the instructions for medical use.

How to contact your eye care clinic:

Contact:

Telephone:

Address:

E-mail:

Date of preparation: June 2022
Version number 481191/VSI/A4/06.2022/240 v8.1
Published: September 2022
Quantities: 240
"Help to the health care professionals. Issued as a part of the Risk Management Plan.
This is not promotional material.
Before prescribing this medicine, please read the instructions for medical use.

If you notice about any side effects, consult with your doctor, nurse or pharmacist. This also concerns to side effects that are not described in the leaflet insert. You can report about side effects directly online to Scientific Centre of Drug and Medical Technology Expertise named after Gabrielyan with the following link: www.pharm.am or call to the hotline: phone numbers: (+374 10) 20 05 05 and (+374 96) 22 05 05.
For reporting about side effects you can also contact Novartis Contact Person for Pharmacovigilance in Armenia. Phone: (+374 11) 51 90 70
Email: drugsafety.cis@novartis.com

Date of preparation: June 2022
Version number 481191/VSI/A4/06.2022/240 v8.1
Published: September 2022
Quantities: 240
"Help to the health care professionals. Issued as a part of the Risk Management Plan.
This is not promotional material.
Before prescribing this medicine, please read the instructions for medical use.

NOVARTIS

